Economics of Total Hip Arthroplasty: Review

Abstract

This review article focuses on issues of economic analysis in providing care to patients requiring total hip arthroplasty. A large number of factors affecting the final financial result force us to look at economic research in the field of arthroplasty with a certain degree of criticality. At the same time, the existing financing systems cannot fully take into account all the possible costs arising from total hip arthroplasty. For this reason, studies concerning revision total hip arthroplasty are of particular interest, where treatment costs can vary significantly depending on the etiology and complexity of the case. These differences are reflected in the works of authors from France, Germany and Great Britain, who compared the treatment costs of patients with septic and aseptic revisions. Very different data both between countries and within the same country well demonstrate the need for a critical approach to the results of cost-effectiveness studies, QALYs based on Markov and other models, as the quality of the original data can be highly variable and reproduce the error of the initially incorrect price structure. At the same time, the rapidly increasing number of operations of primary and revision hip arthroplasty and, accordingly, the increasing economic costs of these operations require clear and effective economic criteria for their evaluation. The formation and application of these criteria will be the purpose of further research.

Keywords

total hip arthroplasty / revision total hip arthroplasty / economic analysis

References

[1] Dittmann H. [Analysis of the conceptual structure of the DRG payments from a cost-accounting point of view]. Gesundheitsökonomie Qualitätsmanagement. 2016;21(03):150-157. (In German). doi: 10.1055/s-0035-1553731.

[2] Fernández-Fernández R., Cruz-Pardos A., García-Rey E. Revision Total Hip Arthroplasty: Epidemiology and Causes. In: Rodríguez-Merchán, E. (eds.) Revision Total Joint Arthroplasty. Springer, Cham; 2020. p. 43-57. doi: 10.1007/978-3-030-24773-7_4.

[3] Hanstein T., Kumpe O., Mittelmeier W., Skripitz R. [Hybrid and uncemented hip arthroplasty: Contribution margin in the German lump sum reimbursement system]. Orthopade. 2015;44(8):617-622. (In German). doi: 10.1007/s00132-015-3139-3.

[4] Diagnosis-related Groups in Europe: Moving towards transparency, efficiency and quality in hospitals (European Observatory on Health Systems and Policies Series). Quentin W., Busse R., Geissler A. (eds.). McGraw-Hill; 2011. Ch. 2, 8. p. 9-21; 37-58.

[5] Stargardt T. Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries. Health Econ. 2008;17(1 Suppl):S9-20. doi: 10.1002/hec.1328.

[6] Sereda A.P., Bogdan V.N., Andrianova M.A., Berenstein M. [Treatment of Periprosthetic Infection: Where and Who?] Travmatologiya i ortopediya Rossii [Traumatology and Orthopedics of Russia]. 2019;(4):33-55. (In Russian). doi: 10.21823/2311-2905-2019-25-4-33-55.

[7] Середа А.П., Богдан В.Н., Андрианова М.А., Беренштейн М. Лечение перипротезной инфекции: где и кто? Травматология и ортопедия России. 2019;(4): 33-55. doi: 10.21823/2311-2905-2019-25-4-33-55.

[8] Haenle M., Skripitz C., Mittelmeier W., Skripitz R. [Economic impact of infected total hip arthroplasty in the German diagnosis-related groups system]. Orthopade. 2012;41(6):467-476. (In German). doi: 10.1007/s00132-012-1939-2.

[9] Bozic K.J., Kurtz S.M., Lau E., Ong K., Chiu V., Vail T.P. et al. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res. 2010;468(1):45-51. doi: 10.1007/s11999-009-0945-0.

[10] Bozic K.J., Kurtz S.M., Lau E., Ong K., Vail T.P., Berry D.J. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91(1):128-133. doi: 10.2106/JBJS.H.00155.

[11] Shubnyakov I.I., Riahi A., Denisov A.O., Korytkin A.A., Aliyev A.G., Veber E.V. et al. [The Main Trends in Hip Arthroplasty Based on the Data in the Vreden’s Arthroplasty Register from 2007 to 2020]. Travmatologiya i ortopediya Rossii [Traumatology and Orthopedics of Russia]. 2021;27(3):119-142. (In Russian). doi: 10.21823/2311-2905-2021-27-3-119-142.

[12] Шубняков И.И., Риахи А., Денисов А.О., Корыткин А.А., Алиев А.Г., Вебер Е.В. и др. Основные тренды в эндопротезировании тазобедренного сустава на основании данных регистра артропластики НМИЦ ТО им. Р.Р. Вредена с 2007 по 2020 г. Травматология и ортопедия России. 2021;27(3):119-142. doi: 10.21823/2311-2905-2021-27-3-119-142.

[13] Lieb E., Hanstein T., Schuerings M., Trampuz A., Perka C. [Reduction of Treatment Duration in Periprosthetic Infection with a Fast-Track Concept Is Economically Not Feasible]. Z Orthop Unfall. 2015;153(6):618-623. (In German). doi: 10.1055/s-0035-1557858.

[14] Maradit Kremers H., Visscher S.L., Moriarty J.P., Reinalda M.S., Kremers W.K., Naessens J.M. et al. Determinants of direct medical costs in primary and revision total knee arthroplasty. Clin Orthop Relat Res. 2013;471(1):206-214. doi: 10.1007/s11999-012-2508-z.

[15] Fisman D.N., Reilly D.T., Karchmer A.W., Goldie S.J. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis. 2001;32(3):419-430. doi: 10.1086/318502.

[16] Haenle M., Skripitz C., Mittelmeier W., Skripitz R. Economic impact of infected total knee arthroplasty. ScientificWorldJournal. 2012;2012:196515. doi: 10.1100/2012/196515.

[17] Klouche S., Sariali E., Mamoudy P. Total hip arthroplasty revision due to infection: a cost analysis approach. Orthop Traumatol Surg Res. 2010;96(2):124-132. doi: 10.1016/j.rcot.2010.02.005.

[18] Vanhegan I.S., Malik A.K., Jayakumar P., Ul Islam S., Haddad F.S. A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. J Bone Joint Surg Br. 2012;94(5):619-623. doi: 10.1302/0301-620X.94B5.27073.

[19] Assmann G., Kasch R., Maher C.G., Hofer A., Barz T., Merk H. et al. Comparison of health care costs between aseptic and two stage septic hip revision. J Arthroplasty. 2014;29(10):1925-1931. doi: 10.1016/j.arth.2014.04.043.

[20] Kasch R., Assmann G., Merk S., Barz T., Melloh M., Hofer A. et al. Economic analysis of two-stage septic revision after total hip arthroplasty: What are the relevant costs for the hospital’s orthopedic department? BMC Musculoskelet Disord. 2016;17:112. doi: 10.1186/s12891-016-0962-6.

RIGHTS & PERMISSIONS

Eco-Vector